{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T12:00:35Z","timestamp":1785499235919,"version":"3.56.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Secondary osteoporosis is a major but frequently under-recognized contributor to skeletal fragility, particularly in men, premenopausal women, patients with fragility fractures at unexpectedly preserved bone mineral density, and individuals with rapid bone loss or inadequate response to standard therapy. Endocrine disorders are among the leading causes because they affect bone remodeling, mineral metabolism, sex steroid signaling, glucocorticoid pathways, insulin-like growth factor activity, and parathyroid hormone regulation. Management requires both correction of the underlying endocrine disorder and pharmacological treatment of skeletal fragility according to fracture risk. This review provides a clinically oriented and guideline-informed synthesis of endocrine-related secondary osteoporosis, with a focus on disease-specific skeletal phenotypes, diagnostic red flags, and targeted management strategies. Particular emphasis is placed on the concept of bone quality as a major determinant of fracture risk and on the limitations of conventional tools such as BMD and FRAX in this setting. We propose a practical clinical framework that integrates endocrine phenotype, vertebral imaging, trabecular bone score, and biochemical assessment into fracture-risk stratification and therapeutic decision-making. This approach supports a shift from a purely densitometric model toward a mechanism-based strategy, enabling improved identification of high- and very-high-risk patients and facilitating the appropriate use of anabolic and antiresorptive therapies.<\/jats:p>","DOI":"10.3389\/fendo.2026.1869556","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:34:50Z","timestamp":1785497690000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Endocrine-related osteoporosis: bone quality, clinical phenotype, and targeted management"],"prefix":"10.3389","volume":"17","author":[{"given":"Ivan Raffaele","family":"Cincione","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Foggia","place":["Foggia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Marcantonio","sequence":"additional","affiliation":[{"name":"Prevention and Protection Area, University of Naples Federico II","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcellino","family":"Monda","sequence":"additional","affiliation":[{"name":"Unit of Dietetics and Sports Medicine, Department of Experimental Medicine, Section of Human Physiology, Universit\u00e0 degli Studi della Campania \u201cLuigi Vanvitelli\u201d","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Polito","sequence":"additional","affiliation":[{"name":"Department of Psychology and Health Sciences, Pegaso Telematic University","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Casillo","sequence":"additional","affiliation":[{"name":"Unit of Dietetics and Sports Medicine, Department of Experimental Medicine, Section of Human Physiology, Universit\u00e0 degli Studi della Campania \u201cLuigi Vanvitelli\u201d","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta","family":"Messina","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, University of Campania \u201cLuigi Vanvitelli\u201d","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta","family":"Monda","sequence":"additional","affiliation":[{"name":"Department of Human Science and Quality of Life Promotion, San Raffaele Telematic University","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorenzo","family":"Moscatelli","sequence":"additional","affiliation":[{"name":"Department of Education and Sport Sciences, Pegaso Telematic University","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Messina","sequence":"additional","affiliation":[{"name":"Unit of Dietetics and Sports Medicine, Department of Experimental Medicine, Section of Human Physiology, Universit\u00e0 degli Studi della Campania \u201cLuigi Vanvitelli\u201d","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Panico","sequence":"additional","affiliation":[{"name":"Loreto Crispi Endocrinology Unit, ASL Napoli 1 Centro","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1210\/endrev\/bnab028","article-title":"Secondary osteoporosis","volume":"43","author":"Ebeling","year":"2022","journal-title":"Endocr Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-023-02056-w","article-title":"Bone quality in endocrine diseases: determinants and clinical relevance","volume":"46","author":"Cianferotti","year":"2023","journal-title":"J Endocrinol Invest"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-0118","article-title":"Management of endocrine disease: secondary osteoporosis: pathophysiology and management","volume":"173","author":"Mirza","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/nyas.13572","article-title":"Bone quality changes associated with aging and disease: a review","volume":"1410","author":"Boskey","year":"2017","journal-title":"Ann N Y Acad Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-018-4405-0","article-title":"Risk-equivalent T-score adjustment for using lumbar spine trabecular bone score (TBS): the Manitoba BMD registry","volume":"29","author":"Leslie","year":"2018","journal-title":"Osteoporos Int"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2015.06.008","article-title":"Fracture risk prediction by non-BMD DXA measures: the 2015 ISCD official positions part 2: trabecular bone score","volume":"18","author":"Silva","year":"2015","journal-title":"J Clin Densitom"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2176","article-title":"Trabecular bone score: a noninvasive analytical method based upon the DXA image","volume":"29","author":"Silva","year":"2014","journal-title":"J Bone Miner Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00198-018-4686-3","article-title":"Radiofrequency echographic multispectrometry compared with dual X-ray absorptiometry for osteoporosis diagnosis on lumbar spine and femoral neck","volume":"30","author":"Di Paola","year":"2019","journal-title":"Osteoporos Int"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.12.1383","article-title":"Oral corticosteroids and fracture risk: relationship to daily and cumulative doses","volume":"39","author":"van Staa","year":"2000","journal-title":"Rheumatology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00097","article-title":"Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy","volume":"39","author":"Hardy","year":"2018","journal-title":"Endocr Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1800214","article-title":"Glucocorticoid-induced osteoporosis","volume":"379","author":"Buckley","year":"2018","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvae137","article-title":"Response to commentary \u201cVasopressin deficiency following operated craniopharyngiomas: fear or fatality","volume":"191","author":"Fountas","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/art.42646","article-title":"2022 American College of Rheumatology guideline for the prevention and treatment of Glucocorticoid\u2010induced osteoporosis","volume":"75","author":"Humphrey","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1001\/jama.2015.5161","article-title":"Subclinical thyroid dysfunction and fracture risk","volume":"313","author":"Blum","year":"2015","journal-title":"JAMA"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1089\/105072503322238854","article-title":"Hyperthyroidism, bone mineral, and fracture risk\u2014a meta-analysis","volume":"13","author":"Vestergaard","year":"2003","journal-title":"Thyroid"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01094-9","article-title":"Evidence-based guideline for the management of osteoporosis in men","volume":"20","author":"Fuggle","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-4255","article-title":"Trabecular bone score (TBS)\u2014a novel method to evaluate bone microarchitectural texture in patients with primary hyperparathyroidism","volume":"98","author":"Silva","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1841","article-title":"Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women","volume":"28","author":"Stein","year":"2013","journal-title":"J Bone Miner Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4677","article-title":"Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the fifth international workshop","volume":"37","author":"Bilezikian","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO chronic kidney disease\u2013mineral and bone disorder (CKD-MBD) guideline update: what\u2019s changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"key":"B22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/ndt\/gfaa192","article-title":"European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4\u2013G5D","volume":"36","author":"Evenepoel","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2337\/db16-0063","article-title":"Skeletal metabolism, fracture risk, and fracture outcomes in type 1 and type 2 diabetes","volume":"65","author":"Sellmeyer","year":"2016","journal-title":"Diabetes"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2016.153","article-title":"Mechanisms of diabetes mellitus-induced bone fragility","volume":"13","author":"Napoli","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1001\/jama.2011.715","article-title":"Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes","volume":"305","author":"Schwartz","year":"2011","journal-title":"JAMA"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2025.101602","article-title":"Trabecular bone score in type 2 diabetes mellitus: an updated systematic review and meta-analysis","volume":"28","author":"Kamrul-Hasan","year":"2025","journal-title":"J Clin Densitom"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1448566","article-title":"Association of trabecular bone score corrected for tissue thickness with glucose metabolism in acromegaly","volume":"15","author":"Ku\u017ema","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-02043","article-title":"Lower trabecular bone score in patients with primary aldosteronism: human skeletal deterioration by aldosterone excess","volume":"103","author":"Kim","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.574151","article-title":"Primary aldosteronism and bone metabolism: a systematic review and meta-analysis","volume":"11","author":"Shi","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3033","article-title":"Risk of fracture in primary aldosteronism: a population-based cohort study","volume":"32","author":"Wu","year":"2017","journal-title":"J Bone Miner Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0417","article-title":"Primary aldosteronism as a cause of secondary osteoporosis","volume":"177","author":"Salcuni","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11657-025-01588-3","article-title":"The 2024 UK clinical guideline for the prevention and treatment of osteoporosis","volume":"20","author":"Gregson","year":"2025","journal-title":"Arch Osteoporos"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/art.40874","article-title":"Denosumab versus risedronate in glucocorticoid\u2010induced osteoporosis: final results of a twenty\u2010four\u2013month randomized, double\u2010blind, double\u2010dummy trial","volume":"71","author":"Saag","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1336075","article-title":"Denosumab, teriparatide and bisphosphonates for glucocorticoid-induced osteoporosis: a Bayesian network meta-analysis","volume":"15","author":"Dong","year":"2024","journal-title":"Front Pharmacol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1869556\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:34:51Z","timestamp":1785497691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1869556\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":35,"alternative-id":["10.3389\/fendo.2026.1869556"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1869556","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"1869556"}}